Continuing Questions About Esketamine 5 Years After Approval: Response to Ahmed et al.
American Journal of Psychiatry September 1, 2026 DOI: 10.1176/appi.ajp.20260182 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Esketamine |
Abstract
Continuing Questions About Esketamine 5 Years After Approval: Response to Ahmed et al.
Citations in the library
Cites 7
- Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism American Journal of Psychiatry August 29, 2018
- Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability Molecular Psychiatry April 15, 2021
- Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. American Journal of Psychiatry March 1, 2025
- Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions? American Journal of Psychiatry March 1, 2025
- The endogenous opioid system in the medial prefrontal cortex mediates ketamine's antidepressant-like actions. Translational Psychiatry February 12, 2024
and 2 more in the library